There is a small increase in the risk of Guillain-Barré syndrome following vaccination with Abrysvo (Pfizer respiratory syncytial virus (RSV) vaccine) and Arexvy (GSK RSV vaccine) in adults aged 60 years and older. Healthcare professionals should advise all recipients of Abrysvo and Arexvy that they should be alert to signs and symptoms of Guillain-Barré syndrome and, if they occur, to seek immediate medical attention as it requires urgent treatment in hospital.
Similar Posts
Medicines marketing authorisation: change of ownership
How to change the ownership from one marketing authorisation (MA) holder to another.
AI breakthroughs drive expansion of ‘Airlock’ testing programme to support AI-powered healthcare innovation
MHRA opens second round of applications to test cutting-edge AI medical technologies following successful pilot phase.
MHRA begins recruitment for new digital roles at Leeds hub to drive innovation and smarter regulation
New jobs to strengthen innovation, safety and smarter regulation across the UK health and life sciences sector.
MHRA updates guidance for semaglutide prescribers and patients
MHRA updates product information regarding the very rare risk of non-arteritic anterior ischemic optic neuropathy (NAION) in patients taking semaglutide.
Device specific vigilance guidance: Coronary Stents and associated delivery systems
Guidance for manufacturers of coronary stents. It outlines specific scenarios that should be considered when determining if an incident is reportable.
Guidance: Custom-made medical devices in Great Britain
How to comply with the regulatory requirements for manufacturing custom-made medical devices.